We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current APLS market cap is 4.82B. The company's latest EPS is USD -4.3309 and P/E is -9.18.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 44.85M | 94.97M | 110.4M | 146.38M | 172.33M |
| Operating Income | -175.08M | -120.44M | -137.08M | -84.52M | -62.09M |
| Net Income | -177.78M | -122.04M | -140.24M | -85.58M | -66.42M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 250.65M | 66.56M | 75.42M | 396.59M |
| Operating Income | -288.02M | -213.73M | -536.28M | -594.61M | -517.12M |
| Net Income | -304.71M | -344.87M | -746.35M | -652.17M | -525.63M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 978.87M | 915.58M | 818.22M | 788.73M | 831.93M |
| Total Liabilities | 566.75M | 570.18M | 585.95M | 594.21M | 565.25M |
| Total Equity | 412.12M | 345.4M | 232.27M | 194.52M | 266.68M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 389.25M | 960.57M | 881.77M | 760.22M | 788.73M |
| Total Liabilities | 355.02M | 756.01M | 683.1M | 590.35M | 594.21M |
| Total Equity | 34.23M | 204.56M | 198.66M | 169.87M | 194.52M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -177.62M | -327.78M | -496.86M | -594.74M | -132.98M |
| Investing | -259k | -631k | -678k | -674k | -293k |
| Financing | 391.11M | 392.67M | 398.41M | 394.5M | 108.21M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -211.14M | -160.49M | -563.13M | -513.75M | -594.74M |
| Investing | -1.69M | -316.99M | 247.62M | 59.89M | -674k |
| Financing | 388.54M | 692.18M | 392.24M | 365.66M | 394.5M |
| Market Cap | 4.82B |
| Price to Earnings Ratio | -9.18 |
| Price to Sales Ratio | 12.17 |
| Price to Cash Ratio | 13.74 |
| Price to Book Ratio | 24.81 |
| Dividend Yield | - |
| Shares Outstanding | 121.37M |
| Average Volume (1 week) | 1.61M |
| Average Volume (1 Month) | 1.4M |
| 52 Week Change | 31.75% |
| 52 Week High | 73.80 |
| 52 Week Low | 19.8301 |
| Spread (Intraday) | 2.05 (5.13%) |
| Company Name | Apellis Pharmaceuticals Inc |
| Address |
108 lakeland ave dover, delaware 19901 |
| Website | https://www.apellis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
